Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

Bibliography

• Ferlay J, Autier P, Boniol M, Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;19:581-92
   Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Sharifi N, Dahut WL, Figg WD. The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res 2008;14:4691-3
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB, Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;26:2544-9
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007;4:92-100
   PubMedGoogle Scholar
• Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009;15:3251-5
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61
   PubMed Web of Science ®Google Scholar
• Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005;95:1327-35
   PubMed Web of Science ®Google Scholar
• Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005;95:1320-6
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-95
   PubMed Web of Science ®Google Scholar
• Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58
   PubMed Web of Science ®Google Scholar
• Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 2008;124:1-6
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: prostate cancer, V2.2009. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [accessed August 2009]
   Google Scholar
• Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-79
   PubMed Web of Science ®Google Scholar
• Saad F, Adachi JD, Brown JP, Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008;26:5465-76
   PubMed Web of Science ®Google Scholar
• Basch EM, Somerfield MR, Beer TM, American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313-8
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008;19:vii91-vii95
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol 2008;26:420-5
   PubMed Web of Science ®Google Scholar
• Saad F, Higano CS, Sartor O, The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006;4:257-62
   PubMed Web of Science ®Google Scholar
• Saad F, Chen YM, Gleason DM, Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-6
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F, Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201
   PubMed Web of Science ®Google Scholar
• Porter AT, McEwan AJ, Powe JE, Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid RH, Hoskin PJ, Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer ES, Yang YC, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13:6396-403
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer E, de WR, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010;16:203-11
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965-70
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Tannock IF, Wit RD, The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010;46(3):517-25
   Google Scholar
• Asim M, Siddiqui IA, Hafeez BB, Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008;27:3596-604
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna NS, Witton CJ, Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003;9:5271-81
   PubMed Web of Science ®Google Scholar
• Tatarov O, Mitchell TJ, Seywright M, SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540-9
   PubMed Web of Science ®Google Scholar
• Lee LF, Louie MC, Desai SJ, Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197-205
   PubMed Web of Science ®Google Scholar
• DaSilva J, Gioeli D, Weber MJ, The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res 2009;69:7402-11
   PubMed Web of Science ®Google Scholar
• Lee LF, Guan J, Qiu Y, Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21:8385-97
   PubMed Web of Science ®Google Scholar
• Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434-40
   PubMed Web of Science ®Google Scholar
• Horne WC, Neff L, Chatterjee D, Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol 1992;119:1003-13
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Sanjay A, Neff L, Src kinase activity is essential for osteoclast function. J Biol Chem 2004;279:17660-6
   PubMed Web of Science ®Google Scholar
• Boyce BF, Yoneda T, Lowe C, Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7
   PubMed Web of Science ®Google Scholar
• Soriano P, Montgomery C, Geske R, Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702
   PubMed Web of Science ®Google Scholar
• Schwartzberg PL, Xing L, Hoffmann O, Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 1997;11:2835-44
   PubMed Web of Science ®Google Scholar
• Mohamedali KA, Poblenz AT, Sikes CR, Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res 2006;66:10919-28
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8
   PubMed Web of Science ®Google Scholar
• Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80
   PubMed Web of Science ®Google Scholar
• Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008;8:342-9
   PubMed Web of Science ®Google Scholar
• Chang YM, Bai L, Liu S, Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33
   PubMed Web of Science ®Google Scholar
• Recchia I, Rucci N, Festuccia C, Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003;39:1927-35
   PubMed Web of Science ®Google Scholar
• Slack JK, Adams RB, Rovin JD, Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001;20:1152-63
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Allen J, Breed J, N-(5-chloro-1,3-benzodioxol-4-yl)-7- [2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006;49:6465-88
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Kurzrock R, Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies [abstract 3511]. J Clin Oncol 2009;27:148S
   Web of Science ®Google Scholar
• Lau GM, Lau GM, Yu GL, Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 2009;54:1465-74
   PubMed Web of Science ®Google Scholar
• Brownlow N, Mol C, Hayford C, Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009;23:590-4
   PubMed Web of Science ®Google Scholar
• Vandyke K, Dewar AL, Farrugia AN, Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994-7
   PubMed Web of Science ®Google Scholar
• Araujo JC, Poblenz A, Corn P, Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 2009;8:2153-9
   PubMed Web of Science ®Google Scholar
• Koreckij T, Nguyen H, Brown LG, Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263-8
   PubMed Web of Science ®Google Scholar
• Yang JC, Ok JH, Busby JE, Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60
   PubMed Web of Science ®Google Scholar
• de Vries TJ, Mullender MG, van Duin MA, The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009;7:476-88
   PubMed Web of Science ®Google Scholar
• Evans CP, Bai L, Kung H, Effect of the specific Src kinase inhibitor AZD0530 on osteolytic lesions in prostate cancer. Proc ASCO Genitourinary Cancers Symposium [abstract 170]. J Urol 2008;179(4):391-391
   Web of Science ®Google Scholar
• Araujo J, Mathew P, Armstrong AJ, Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086 [abstract 7028]. Eur J Cancer 2009;7:415S
   Web of Science ®Google Scholar
• Yu EY, Massard C, Gross M, A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085) [abstract 5147]. J Clin Oncol 2009;27:270S
   Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Longmate J, Evans CP, A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009;20:179-84
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M, Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 2009; published online September 23 2009, doi: 10.1359/jbmr.090830
   Google Scholar
• Wang XD, Reeves K, Luo FR, Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255
   PubMedGoogle Scholar
• Guo Z, Dai B, Jiang T, Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-19
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Castoria G, Di DM, Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17
   PubMed Web of Science ®Google Scholar
• Mendiratta P, Mostaghel E, Guinney J, Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009;27:2022-9
   PubMedGoogle Scholar
• Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer 2009;115:3046-57
   PubMed Web of Science ®Google Scholar
• Elsberger B, Tan BA, Mitchell TJ, Is expression or activation of Src kinase associated with cancer-specific survival in ER, PR and HER2-negative breast cancer patients? Am J Pathol 2009;175:1389-97
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Kerege AA, French JD, Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94:2199-203
   PubMed Web of Science ®Google Scholar